Patent GB-1022967-A (GB)
Title: Thiocelestosamine derivatives
IPC: C08G18/50
Filed: 1964-04-07
Abstract: b -Hydroxyethylthiocelestosaminide of the formula <FORM:1022967/C3/1> and N-acyl derivatives thereof may be reacted with isocyanates such as an excess of toluene diisocyanate to form urethanes or ureas, which are further reacted with polyol ethers or polyol esters and then polymerized to form polyurethane resins. Alternatively, the thiocelestosaminide derivative may be mixed with the polyol and then with the toluene diisocyanate, or it can be reacted with an alkylene oxide to form a polyoxyalkylated derivative, which is then reacted with the toluene diisocyanate to form a polyurethane.  b  - Hydroxyethylthio-celestosaminide thiocyanate may also be condensed with formaldehyde to form polymers.ALSO:The invention comprises b -hydroxyethylthiocelestosaminide of the formula <FORM:1022967/C2/1> salts thereof with hydrochloric, sulphuric, phosphoric, thiocyanic, fluosilicic, acetic, succinic, citric, lactic, maleic, fumaric, pamoic, cholic, palmitic, mucic, camphoric, glutaric, glycolic, phthalic, tartaric, lauric, stearic, salicylic, 3-phenylsalicylic, 5-phenylsalicylic, 3 - methyl - glutaric, ortho - sulphobenzoic, cyclohexanesulphamic, cyclopentanepropionic, 1,2 - cyclohexanedicarboxylic, 4 - cyclohexenecarboxylic, octadecenylsuccinic, octenylsuccinic, methanesulphonic, benzenesulphonic, Reinecke's, azobenzenesulphonic, octadecylsulphuric and picric acids; salts thereof with penicillin and benzylpenicillin; hydrazine solvates thereof; and N-acyl derivatives derived from arginine, lysine, listidine, valine, leucine, isoleucine, phenylalamine, threanine, methionine, tryptophan, hydroxyproline, aspartic acid, glutamic acid, hydroxyglutamic acid, alanine, norleucine, serine, cystine, tyrosine, proline and C1-18 saturated and unsaturated fatty acids. The above compounds are prepared by subjecting celestrietin or desalicetin to hydrazinolysis with hydrazine hydrate to form b -hydroxyethylthiocelestosaminide hydrazine solvate, from which unsolvated b -hydroxy-ethylthiocelestosaminide is obtained by treatment with dimethylformamide.  Further treatment with acylating agents provides N-acyl-b -hydroxy-ethylthio-celestosaminides. Specified acylating agents are anhydrides, acid halides, esters or mixed anhydrides. Esters of a -amino acids are preferably para-nitrophenyl and cyanomethyl esters in which the amino groups are protected by means of trifluoroacetyl, carbobenzoxy, carbo - t - butoxy or triphenylmethyl groups. The mixed anhydrides are preferably those formed from a desired acid and a non-reactive acid such as ethyl hydrogen carbonic or paratoluenesulphonic acids.  The formation of salts between b  - hydroxyethyl - thiocelestosaminide and penicillins (e.g. benzylpenicillin) enable the latter to be isolated and purified.  Reaction of b -hydroxyethylthiocelestosaminide with racemic aids provides mixtures of diastereoisomeric acid addition salts which can be separated by fractional crystallization.  The formation of N-acyl derivatives and their subsequent deacylation by hydrazinolysis or alkaline hydrolysis may be used for the purification of the b -hydroxyethylthiocelestosaminide. Both b -hydroxyethylthiocelestosaminide and N-acyl derivatives thereof may be reacted with isocyanates (e.g. excess toluene diisocyanate) to urethanes and ureas, or with alkylene oxides (e.g. ethylene or propylene oxides) to form polyoxyalkylated derivatives.